Full Text Sources
Adiponectin (ApN) is a multifunctional adipokine. However high, rather than low, concentrations of ApN are unexpectedly found in patients with chronic kidney disease (CKD) via an as yet unknown mechanism and the role of ApN in CKD is unclear. We, herein, investigated the effect of ApN overexpression on the progressive renal injury resulted from deoxycorticosterone acetate-salt (DOCA) and angiotensin II (Ang-II) infusion using a transgenic, inducible ApN-overexpressing mouse model. Three groups of mice (wild type receiving no infusion (WT), WT and cyp1a1 ApN transgenic mice (ApN-Tg) receiving DOCA+Ang-II infusion (WT/DOCA+Ang-II and ApN-Tg/DOCA+Ang-II)) were assigned to receive a normal food containing 0.15% of the transgene inducer indol-3-carbinol (I3C) for 3 weeks. The I3C-induced ApN-Tg/DOCA+Ang-II mice, not the WT or WT/DOCA+Ang-II mice, overexpressing ApN in liver resulted in 3.15-fold increases in circulating ApN than non-transgenic controls. Of note, these transgenic mice receiving DOCA+Ang-II infusion were still hypertensive but had much less albuminuria and glomerular and tubulointerstitial fibrosis, which were associated with ameliorated podocyte injury determined by ameliorated podocyte loss and foot process effacement; and alleviated tubular injury determined by ameliorated mRNA overexpression of KIM-1 and NGAL and mRNA decreases of cubilin and megalin in tubular cells, compared with WT/DOCA+Ang-II mice. In addition, renal production of NF-kB-p65, NAPDH oxidase-2 and p47phox, and MAPK-related cellular proliferation, which were induced in WT/DOCA+Ang-II mice, were markedly reduced in ApN-Tg/DOCA+Ang-II mice. These results indicate that elevated ApN in CKD mouse model is renal protective. Enhancing adiponectin production or signaling may have therapeutic potential for CKD.
PMID: 29873514 [PubMed - as supplied by publisher]